
THE 3’ END PROTHROMBIN GENE VARIANTS IN SERBIAN
PATIENTS WITH IDIOPATHIC THROMBOPHILIA Aradjanski M1, Djordjevic V1, Pruner I1,*, Tomic B1, Gvozdenov M1, Kovac M2,3, Radojkovic D1 *Corresponding Author: Dr. Iva Pruner, Institute of Molecular Genetics and Genetic Engineering, Vojvode Stepe
444A, PO Box 23, 11010 Belgrade, Serbia. Tel: +381-11-397-6658. Fax: +381-11-397-5808. E-mail: iva.pruner@
gmail.com page: 43 download article in pdf format
|
Abstract
Thrombophilia is a multifactorial disorder that
arises from the interaction of acquired and genetic
risk factors. Despite the significant efforts made to
understand the etiology of this disease, there are still
a certain number of patients suffering from idiopathic
thrombophilia. The aim of this study was to screen
the 3’ end of the prothrombin (FII) gene, which is
susceptible to gain-of-function mutations due to its
non canonical architecture, in patients with idiopathic
thrombophilia and to determine its eventual role in
the pathogenesis of thrombophilia.
This study was carried out in 100 patients with
idiopathic thrombophilia and 100 healthy controls.
DNA variants in the 715 bp long region of the 3’ end
of the prothrombin gene were identified by sequencing.
In our study, we detected two variants: A19911G
and C20068T. The frequency of the A19911G gene
variant was slightly increased in the group of patients
compared to controls, however with no statistically
significant difference compared to controls [odds
ratio (OR) = 1.06; 95% confidence interval (95%
CI) 0.53-2.13]. Heterozygous carriers of the FII
C20068T gene variant were four times more frequent
in patients (4.0%) than in controls (1.0%), but this
difference did not reach statistical significance (OR
= 4.12; 95% CI 0.45-37.57). Our findings suggest
that variant A19911G is not a significant risk factor,
while C20068T may represent a potential risk factor
for idiopathic thrombophilia. To confirm our results,
further studies should be conducted in a larger cohort
of patients.
|
|
|
|



 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|